other material
confidence high
sentiment positive
materiality 0.75
Immuneering reports 64% OS at 12 months in Phase 2a pancreatic cancer trial; median OS not reached
Immuneering Corp
- 64% OS at 12 months (SOC 35%) in 34 first-line pancreatic cancer patients at 320 mg atebimetinib + mGnP; median OS not reached.
- Median PFS 8.5 months; 94% OS at 6 months (SOC 67%) and 83% at 9 months (SOC ~47% estimated).
- Grade ≥3 TEAEs in ≥10%: anemia (18%) and neutropenia (18%); no Grade 5 events, no new safety signals.
- Near-term milestones: Phase 3 enrollment start mid-2026; >50 patient data in H1 2026; NSCLC trial start H2 2026.